BE-POSITIVE: Beyond progression after tyrosine kinase inhibitor in EGFR- positive non small cell lung cancer patients

BE-Positive is the first multicenter observational study reporting outcomes of therapies in a “real-life Caucasian EGFR-mutated population”, highlighting the need of further researches about new treatment strategies in this setting.